Research Use Only. This page is a comparative laboratory-research resource. It does not provide advice about nootropic use, anxiety, sleep, focus, memory, cognition, performance, administration, dosing or human outcomes.
Semax, Selank and DSIP are grouped as neuroregulatory research compounds, but that shared catalogue location is not a claim of common mechanism, comparable evidence depth or interchangeable experimental use. A useful comparison distinguishes origin/class, exact form, literature pathway, analytical requirements and the limitation that accompanies each evidence layer.
Comparison matrix
| Comparison field | Semax | Selank | DSIP |
|---|---|---|---|
| Commercial owner | Semax 10mg | Selank 10mg | DSIP 10mg |
| Entity origin / class | Literature describes Semax as a synthetic regulatory peptide. Exact supplied form, sequence integrity and counter-ion need product-specific verification. | Literature describes Selank as a synthetic heptapeptide analogue. Keep exact product form separate from a generic literature entity. | DSIP is a named short peptide in neuroregulatory research literature; its historical origin and biological role remain subjects of uncertainty. |
| Structure / mass field | Do not populate a mass or counter-ion from a generic listing without the product record. | Do not infer sequence integrity or molecular mass from the category name alone. | Verify the supplied peptide form and molecular mass against documentation before making a product-specific statement. |
| Research-pathway context | Published work examines peptide-associated gene-expression and biochemical pathway questions in experimental systems. | Published work discusses receptor, immunological and neuroregulatory hypotheses; evidence layers should remain explicit. | Literature addresses neuroregulatory and physiological hypotheses, while also recognising unresolved aspects of the entity’s biology. |
| Evidence layer | Biochemical and preclinical literature; no direct transfer to human outcomes. | Biochemical and preclinical contexts; do not turn a mechanistic hypothesis into a commercial benefit claim. | Mechanistic and historical research context with material translation uncertainty. |
| Analytical verification | Batch documentation should support the declared peptide identity and chromatographic composition for the specified form. | Use method-aware HPLC and MS interpretation; no generic purity threshold is implied. | Documentation should distinguish the declared short peptide from an unverified generic name. |
| Handling distinction | Use product documentation and general laboratory compatibility principles; this matrix does not give a preparation recipe. | Use product documentation and the relevant handling guide; avoid importing a solvent protocol from another peptide. | Use product documentation; do not infer stability windows or compatibility from its category position. |
| Major limitation | Research pathways and evidence depth do not establish a consumer or clinical outcome. | Hypothesis-level literature is not evidence of a defined product effect. | Unresolved aspects of biological origin and role make careful evidence-layer labelling particularly important. |
Entity-by-entity evidence context
Semax experimental literature includes gene-expression and biochemical-model work.[1] That evidence belongs to the model and research condition reported in the source; it does not establish the identity, form or outcome of a separate RUO product.
Selank literature discusses a synthetic peptide entity and multiple mechanistic hypotheses.[2] The correct comparison question is therefore which pathway or assay context a source actually reports, not whether a product should be selected for a claimed human effect.
DSIP has long been discussed as a neuroregulatory peptide with unresolved questions about its biology.[3] That uncertainty is a research feature, not a gap to fill with unsupported claims.
How to choose the correct research material for an experimental design
Start by matching the literature entity to the experimental question. State whether the study concerns a defined peptide identity, a reported biochemical pathway, a model-specific readout or an analytical verification problem. Then confirm that the exact supplied form, counter-ion and product documentation are sufficient for the work. If the evidence is model-limited or mechanistically uncertain, retain that limitation in the experimental record.
The exact commercial owners remain the appropriate destination for product-specific information: Semax, Selank and DSIP. Do not add Klow to this comparison; its product identity remains a separate unresolved matter.
Documentation and analytical context
For batch-specific analytical documentation, use the Certificate of Analysis portal. For method interpretation, use the analytical release criteria guide. HPLC and MS can contribute different evidence about a declared peptide material; neither replaces a validated product specification or establishes a human-use claim.
What this comparison does not establish
This matrix does not compare sleep, anxiety, focus, memory, cognitive or performance outcomes. It does not provide a preparation method, administration route, dosing or subject schedule. It does not assume that the three entities have equal evidence depth or that a generic literature entity confirms the exact Core Research product form.
Related research resources
- Specialist Research Compounds Catalogue
- Semax 10mg, Selank 10mg and DSIP 10mg
- Batch Certificate of Analysis Verification
- Analytical release criteria
References
- Gusev FE, et al. The peptide Semax affects expression of genes related to immune and vascular systems in rat brain focal ischaemia. BMC Genomics. 2014. DOI. Used for experimental evidence-layer context only.
- Vas’kova KA, et al. Peptide-based anxiolytics: molecular aspects of heptapeptide Selank biological activity. Protein and Peptide Letters. 2018. DOI. Used for identity and hypothesis context only.
- Monnier M, et al. Delta sleep-inducing peptide: a still unresolved riddle. Journal of Neurochemistry. 2006. DOI.